IL-6 and IGF-1 are Independent Prognostic Factors of Liver Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients

García-Galiano, David; Sánchez-Garrido, Miguel A.; Espejo, Isabel; Montero, J.L.; Costán, Guadalupe; Marchal, Trinidad; Membrives, Antonio; Gallardo‐Valverde, José María; Muñoz‐Castañeda, Juan R.; Arévalo, Eugenio; Mata, Manuel de la; Muntané, Jordi

doi:10.1007/s11695-007-9087-1

Cited by 101 publications

(86 citation statements)

References 54 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemerin levels are significantly elevated in morbidly obese women characterized by a significant activity score for nonalcoholic fatty liver disease and fibroinflammation. We could not find changes in leptin or adiponectin in patients with liver pathology in this study, whereas higher IL-6 secretion could be shown to be associated with steatosis, corroborating other studies (16). The mechanism by which increased adipose tissue mass and the concomitant increase of adipokines might be involved in hepatosteatosis includes the infiltration of macrophages in adipose tissue (8,17).…”

Section: Discussionsupporting

confidence: 89%

Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery

Sell

Divoux

Poitou

et al. 2010

The Journal of Clinical Endocrinology &Amp; Metabolism

228

195

View full text Add to dashboard Cite

Context: Chemerin is a new adipokine involved in in vitro adipogenesis and insulin resistance and associates with body mass index (BMI) in vivo.Objective: We investigated the role of chemerin in morbid obesity, associated metabolic diseases (insulin resistance, hepatic diseases), and postsurgery-induced weight loss. Setting:This was a prospective study performed at a university hospital.Subjects: Subjects included 60 obese female patients (BMI 50.0 Ϯ 1.0 kg/m Ϫ2 ) being candidates for gastric bypass.Study Design: Patients were examined before and 3, 6, and 12 months after surgery. In 27 patients, chemerin was measured after 2 yr.Main Outcome: Outcomes included chemerin, anthropometric parameters, homeostasis model assessment for insulin resistance index (HOMA-IR), cholesterol, high-density lipoprotein, triglycerides, C-reactive protein, adipokines at all time points; and liver histology and macrophage content in fat at baseline. Results:Chemerin was substantially elevated in obese patients compared with nonobese persons (353.8 Ϯ 18.0 vs. 191 Ϯ 14 ng/ml, P Ͻ 0.001). Preoperatively, chemerin concentrations correlated positively with BMI, C-reactive protein, IL-6, HOMA-IR, and the amount of omental macrophages and negatively with high-density lipoprotein levels. Baseline chemerin was elevated in patients with a significant activity score for nonalcoholic fatty liver disease, portal inflammation, fibrosis, and fibroinflammation. After surgery, chemerin decreased significantly to 253.0 Ϯ 14.9 ng/ml after 1 yr and pursued its decrease in patients studied for 2 yr. After surgery, chemerin concentrations positively correlated with triglycerides. The strong decrease of chemerin in the 3 months after surgery was associated with the decrease in HOMA-IR and blood glucose. Conclusions:Chemerin concentrations are elevated in morbidly obese patients and correlated with insulin resistance and markers of liver pathology. Chemerin plasma concentrations decreased after bariatric surgery. This study suggests that chemerin might mediate metabolic alterations in obesity, drastically improving after gastric bypass. O besity is one of the most serious health hazards and frequently accompanied by metabolic disturbances (1). Increased adipose tissue mass, especially in the visceral compartment, is characterized by altered metabolic and endocrine function leading to an increased secretion of proinflammatory adipokines. These secreted molecules may be factors underlying the association between increased body fat and metabolic complications such as insulin resistance in peripheral organs or ectopic fat accumulation. Chemerin is a recently described adipokine

show abstract

Section: Discussionsupporting

confidence: 89%

Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery

Sell

Divoux

Poitou

et al. 2010

The Journal of Clinical Endocrinology &Amp; Metabolism

228

195

View full text Add to dashboard Cite

show abstract

“…Insulin pendent prognostic factors of liver steatosis and NASH in morbidly obese patients [67]. In addition, hyaluronic acid levels, which are a fibrotic marker, showed a negative correlation with IGF-I and the IGF-I/IGFBP-3 ratio in patients with NAFLD [24].…”

Section: Igf-i Action In Livermentioning

confidence: 99%

Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver [Review]

Takahashi

2012

Endocr J

View full text Add to dashboard Cite

Abstract. Growth hormone (GH) and insulin-like growth factor-I (IGF-I) play essential roles in growth in childhood, and continue to have important metabolic actions in adults. Adult growth hormone deficiency (AGHD) is characterized by increased visceral adiposity, abnormal lipid profiles, premature atherosclerosis, decreased quality of life, and increased mortality. Recently, case reports and several clinical studies suggest that GHD state in adults is associated with an increased prevalence of nonalcoholic fatty liver disease (NAFLD) and progression to nonalcoholic steatohepatitis (NASH) or liver cirrhosis. As a mechanistic insight, growing evidence has revealed that GH as well as IGF-I play essential roles in the liver. Further investigation is necessary to clarify the precise mechanisms by which GH and IGF-I exert their effects in the liver; however, it should be noted that NAFLD/NASH has emerged as an important comorbidity in AGHD.

show abstract

“…Alternatively, lower IGFBP-2 levels may be acting as a marker of increased insulin resistance. With increasing obesity, there is a fall in serum IGF-I levels, probably consequent to impaired hepatocyte function due to development of a fatty-liver and eventually non-alcoholic steatohepatitis (liver disease) [60]. However, the fall in absolute IGF-I levels is very small compared to the relatively large fall in IGFBP-2 levels: the fall in IGF-I, from BMI quartile 3 (which had the highest IGF-I) to BMI quartile 1, was only 5 ng/ml (approximately 10%), whereas IGFBP-2 decreased by 22% per SD increase in BMI.…”

Section: Biological Roles Of Igfs and Igfbps In Prostate Cancermentioning

confidence: 99%

The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study

Rowlands

Holly

Gunnell

et al. 2010

Cancer Causes Control

View full text Add to dashboard Cite

We provide evidence that adiposity and change in body shape through the life course are related to the IGF system, with the largest effect of adiposity being to lower IGFBP-2, a possible marker of insulin resistance. The results suggest that circulating IGF-I levels may not be important mediators of the association of adiposity with aggressive prostate cancer, but the role of IGFBP-2 deserves further investigation.

show abstract

IL-6 and IGF-1 are Independent Prognostic Factors of Liver Steatosis and Non-Alcoholic Steatohepatitis in Morbidly Obese Patients

Abstract: The concentration of glucose, insulin, IL-6 and IGF-1 in blood are useful markers for the selection of patients with liver steatosis or NASH.

Cited by 101 publications

References 54 publications

Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery

Chemerin Correlates with Markers for Fatty Liver in Morbidly Obese Patients and Strongly Decreases after Weight Loss Induced by Bariatric Surgery

Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver [Review]

The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (Prostate testing for cancer and Treatment) study

Contact Info

Product

Resources

About